One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Omeros Corporation logo
Omeros Corporation OMER
$ 16.2 1.95%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Omeros Corporation Income Statement 2025-2008 | OMER

Brief overview of financial results at Omeros Corporation

This overview is based on financial performance over the past five years. According to figures from Omeros Corporation, revenue changed from $539 thousand to $112 million over five years. The cumulative result was +20643%, corresponding to roughly 190.7% per year. The annual growth rate indicates an exceptionally strong top-line trend.

Over the period, EBITDA shifted from −69.7 million dollars to −61.6 million dollars, a change of +11.6%. Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of −12928% and −55.1%. Higher profitability strengthens the quality of operating growth.

Across the five years, the net result shifted from −$73.7 million to −$84.5 million. The loss widened and increased the financial risk.

The five-year change in capitalization reached −12.5%: from 739 million dollars to 647 million dollars. The market became more cautious about the prospects of the business.

What the figures show

Positive developments coexist with areas of weakness. The financial profile benefits from positive operating leverage and sales growth. The most visible risks are a narrow EBITDA buffer and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Omeros Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

671 M 478 M 200 M 215 M 401 M 817 M 647 M 636 M 755 M 375 M 405 M 739 M 342 M 133 M 129 M 118 M - -

Shares

63.5 M 58.2 M 62.7 M 62.7 M 62.3 M 57.2 M 49.5 M 48.6 M 45.5 M 40.4 M 37.6 M 33.2 M 28.6 M 24.2 M 22.2 M 21.4 M - -

Historical Prices

10.6 8.22 3.19 3.43 6.43 14.3 14.1 11.1 19.4 9.92 15.7 24.8 11.3 5.19 3.95 5.52 - -

Net Income

-3.35 M -157 M -118 M 47.4 M 194 M -138 M -84.5 M -127 M -53.5 M -66.7 M -75.1 M -73.7 M -39.8 M -38.4 M -28.5 M -29.3 M -21.1 M -

Revenue

- - - - - - 112 M 29.9 M 64.8 M 41.6 M 13.5 M 539 K 1.6 M 6.02 M 4.52 M 2.1 M 1.44 M -

Cost of Revenue

- - - - - - 865 K 512 K 1.08 M 1.41 M - - - - - - - -

Gross Profit

- - - - - - 111 M 29.4 M 63.7 M 40.2 M 12.5 M - - - 4.52 M - - -

Operating Income

-123 M -167 M -165 M -163 M -174 M -157 M -146 M -112 M -43.9 M -54.3 M -71.2 M -70 M -50.5 M -36.9 M -27.4 M -30.1 M -20.8 M -

Interest Expense

- - 30.8 M 22.7 M 19.7 M 26.8 M 22.7 M 16.3 M 11 M 7.82 M 3.57 M 3.47 M 2.37 M 1.73 M 1.88 M 1.54 M 2.2 M -

EBITDA

-122 M -166 M -164 M -162 M -172 M -155 M -61.6 M -111 M -43.3 M -54 M -71 M -69.7 M -50.2 M -36.6 M -27 M -29.6 M -20.3 M -

Operating Expenses

- - - - - - 174 M 142 M 108 M 94.5 M 83.7 M 70.5 M 52.1 M 42.9 M 31.9 M 32.2 M 22.2 M -

General and Administrative Expenses

41.5 M 47.4 M 49.7 M 50.7 M 54.8 M 49.3 M 64.6 M 51.7 M 52 M 43.8 M 35.3 M 22.6 M 15.8 M 11 M 8.22 M 8.75 M 5.27 M -

All numbers in USD currency

Quarterly Income Statement Omeros Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

58.6 M 71.9 M - 66.3 M 58.6 M 58.1 M 58 M 57.9 M 57.9 M 58.8 M 61.1 M 62.9 M 62.8 M 62.8 M 62.8 M 62.7 M 62.7 M 62.7 M 62.6 M 62.5 M 62.4 M 61.9 M 61.7 M 58.2 M 54.5 M 54.3 M 54.2 M 49.4 M 49.1 M 49 M 49 M 48.6 M 48.4 M 48.3 M 48.2 M 46.3 M 44 M 43.8 M 43.8 M 41.1 M 39.2 M 38.3 M 38 M 37.9 M 37.8 M 36.5 M 34.2 M 34 M 33.9 M 30.9 M 30.4 M 29.8 M 28.2 M 25.9 M 25.9 M 25.8 M 22.5 M 22.4 M 22.4 M 22.2 M 22.2 M 22.4 M

Net Income

-33.5 M 56.1 M - -30.9 M -25.4 M -33.5 M - -32.2 M -56 M -37.2 M - -37.8 M -37.3 M -33.7 M - -17.5 M -30.8 M -33 M - -22.7 M -28.6 M -35.1 M -37.3 M -38.5 M -33.3 M -29 M -29.2 M -16.5 M -14.5 M -24.3 M -23.5 M -39.5 M -33.7 M -30.1 M -16.6 M -7.48 M -14.4 M -53.5 M -19.6 M -14 M -66.7 M 66.7 M -19.8 M -19.9 M -16.7 M -18.7 M -20.7 M -18.3 M -18 M -16.6 M -1.84 M -13.9 M -13.6 M -10.5 M -7.73 M -13.3 M -8.54 M -8.9 M -10.2 M -6.51 M -5.29 M -6.54 M

Revenue

- 9.89 M - - - - - - - - - - - - - - - - - 30 M 28.8 M 21.1 M 10.6 M 26.1 M 13.5 M 23.5 M 33.4 M 29.9 M 26.8 M 21.8 M 22 M 4.61 M 1.66 M 1.59 M 13.8 M 21.7 M 17.2 M 12.3 M 12.9 M 11.3 M 10 M 7.42 M 6.68 M 3.26 M 3.19 M 388 K 180 K 214 K 45 K 100 K 169 K 196 K 140 K 1.1 M 1.58 M 1.42 M 1.53 M 1.5 M 1.14 M 987 K 1.16 M 1.24 M

Cost of Revenue

- 587 K - - - - - - - - - - - - - - - - - 333 K 342 K 263 K - 401 K 147 K 267 K - 278 K 55 K 131 K - 36 K 116 K 203 K - 184 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-32.4 M -17.4 M - -26.4 M -32.4 M -35 M - -35.4 M -59.2 M -39 M - -48.2 M -40.9 M -35.7 M - -50.8 M -37.4 M -35 M - -39.8 M -45.6 M -45.3 M -33.8 M -25.4 M -27.7 M -23.7 M -23.7 M -11.1 M -63.4 M -63.4 M -18.5 M -35.4 M -30.6 M -27.7 M -14.1 M -5.11 M -11.9 M -12.7 M -11.9 M -12 M -10.9 M -19.5 M -18 M -19.3 M -16 M -17.9 M -20 M -17.1 M -17.2 M -15.7 M -13.9 M -13.4 M -13.2 M -10 M -7.53 M -13 M -8.24 M -8.07 M -9.85 M -6.16 M -4.95 M -6.45 M

Interest Expense

- - - - - - - 4.05 M 9.22 M 8.23 M - 7.92 M 7.93 M 7.93 M - 4.93 M 4.93 M 4.94 M - 4.91 M 4.91 M 4.9 M - 6.88 M 5.98 M 5.9 M - 5.72 M 5.53 M 5.6 M - 4.6 M 3.68 M 2.82 M - 2.78 M 2.72 M 2.66 M - 2.14 M 1.86 M 1.38 M - 871 K 937 K 957 K - 944 K 939 K 672 K - 592 K 589 K 587 K - 413 K 453 K 494 K - 528 K 527 K 293 K

EBITDA

-32.2 M -17.2 M - -26.2 M -32.2 M -34.7 M - -35.2 M -59 M -38.8 M - -48 M -40.6 M -35.5 M - -50.5 M -37.2 M -34.8 M - -39.5 M -45.2 M -44.9 M -33.8 M -25 M -27.3 M -23.3 M -23.7 M -10.7 M -62.6 M -63 M -18.5 M -34.8 M -30.2 M -27.5 M -14.1 M -4.73 M -11.7 M -12.6 M -11.9 M -11.8 M -10.8 M -19.4 M -18 M -19.1 M -15.9 M -17.9 M -20 M -16.9 M -17.1 M -15.6 M -13.9 M -13.2 M -13 M -9.95 M -7.53 M -12.8 M -8.08 M -7.98 M -9.85 M -5.83 M -4.72 M -6.28 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - 41 M 40.5 M 40 M 32.3 M 29.3 M 27.9 M 26.8 M 29.1 M 25 M 24.8 M 23.3 M 20.9 M 26.9 M 24.7 M 22.6 M 19.2 M 18.3 M 20.2 M 17.3 M 17.3 M 15.8 M 14.1 M 13.6 M 13.3 M 11.1 M 9.12 M 14.5 M 9.77 M 9.57 M 11 M 7.15 M 6.1 M 7.69 M

General and Administrative Expenses

10.3 M 13.4 M - 10.4 M 10.3 M 11.1 M - 11.3 M 13.8 M 12.3 M - 16.4 M 11.3 M 11.1 M - 12.2 M 13.9 M 11 M - 14 M 15.5 M 12.8 M - 19.8 M 16.9 M 18 M - 16.9 M 16.9 M 14.6 M - 13.2 M 12.7 M 10.9 M - 11.7 M 15.8 M 12.5 M - 10.5 M 10.4 M 11.1 M - 9.05 M 7.89 M 8.99 M - 5.57 M 4.86 M 3.77 M - 4.21 M 3.74 M 3.99 M - 2.74 M 2.21 M 2.32 M - 1.83 M 2.03 M 2.26 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Omeros Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Alector Alector
ALEC
$ 1.84 6.02 % $ 190 M usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Poseida Therapeutics Poseida Therapeutics
PSTX
- - $ 857 M usaUSA
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.06 6.0 % $ 56.9 M usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.98 0.09 % $ 226 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
- - $ 382 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 295.54 1.19 % $ 5.72 B usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Longeveron Longeveron
LGVN
$ 1.39 0.81 % $ 24.4 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.87 1.3 % $ 1.21 B usaUSA
Annovis Bio Annovis Bio
ANVS
$ 0.99 0.95 % $ 20.3 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 257.03 0.42 % $ 1.13 T usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 19.18 0.42 % $ 6.01 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA